Duchesnay Inc. and Tzamal Medical Group Ltd Sign an Agreement for the Drug Diclectin® for the Management of Nausea and Vomiting of Pregnancy 1/16/2013 9:13:22 AM

BLAINVILLE, QC and TEL AVIV, Israel, Jan. 16, 2013 /CNW Telbec/ - Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal
Medical Group has been granted exclusive rights to distribute and sell
throughout the Israeli market the prescription medicine Diclectin® (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated
for the management of nausea and vomiting of pregnancy (NVP).

"We are very pleased to partner with Tzamal Medical Group, a successful
and trusted industry leader in the field of medical and pharmaceutical
specialty products", said Éric Gervais, Executive Vice-President of
Duchesnay Inc. "This strategic collaboration represents an important
milestone in our endeavor to help pregnant women suffering from nausea
and vomiting of pregnancy (NVP). We are excited to enable expectant
mothers within the Israeli market to have access to a proven safe and
effective pharmacological treatment for NVP."

"Diclectin ®, as a delayed release combination proved its impeccable
efficacy and safety in North America / Canada for years and as such
recommended as first choice by both the Society Obstetricians and
Gynaecologists of Canada (SOGC) and the American College of
Obstetricians and Gynaecologists (ACOG)" - said E. Steinberg , CEO of
Tzamal BioPharma Ltd, the pharmaceutical arm of Tzamal Medical Ltd -
"and we are confident that the available solid clinical and safety data
of the drug will allow the Israeli MOH to approve it as the first drug
to address specifically for NVP, a very important unmet need of the
pregnant women up to now".

ABOUT DICLECTIN®

Diclectin®, a delayed-release combination of doxylamine and vitamin B6, is the only antinauseant and antiemetic drug labelled and approved for
use in pregnancy in Canada. Its long and outstanding track record of
safety and efficacy has made Diclectin® the medicine of choice in Canada for over 30 years. In the Drugs in
Pregnancy and Lactation Reference Guide, Briggs has assigned Diclectin® the highest safety rating: "Compatible" or "Category A".

ABOUT NAUSEA AND VOMITING OF PREGNANCY (NVP)

Nausea and vomiting of pregnancy (NVP), commonly called morning
sickness, affects between 70 to 85 percent of pregnant women. If left
untreated, symptoms can sometimes progress to a potentially more
serious condition called hyperemesis gravidarum (HG), which may require
hospitalization. NVP can have a dramatic impact on the emotional and
physical well-being of the expectant woman and her family. NVP has
also been shown to impose an economic burden on healthcare costs and
lost productivity.

ABOUT DUCHESNAY

Duchesnay Inc. is a Canadian specialty pharmaceutical company dedicated
to improve the health and quality of life of pregnant women by working
at advancing maternal-fetal medicine to reduce the risk of birth
defects and by developing safe and effective pharmacological solutions
for use during pregnancy and breastfeeding. For more information, visit
http://www.duchesnay.com/en/.

ABOUT TZAMAL MEDICAL GROUP

Tzamal Medical Group is a leading provider of pharmaceuticals, medical
devices and equipment for the global healthcare industry. Tzamal
Medical Group promotes leading global healthcare and creates leverage
both in the Israeli and global medical markets. For more information,
visit www.tzamal-medical.co.il